当前位置:
X-MOL 学术
›
J. Med. Chem.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Discovery of Novel Celastrol–Imidazole Derivatives with Anticancer Activity In Vitro and In Vivo
Journal of Medicinal Chemistry ( IF 6.8 ) Pub Date : 2022-03-03 , DOI: 10.1021/acs.jmedchem.1c01293
Na Li 1 , Manyi Xu 1 , Lulu Zhang 1 , Zhichao Lei 1 , Cheng Chen 1 , Tianyuan Zhang 1 , Li Chen 1 , Jianbo Sun 1
Journal of Medicinal Chemistry ( IF 6.8 ) Pub Date : 2022-03-03 , DOI: 10.1021/acs.jmedchem.1c01293
Na Li 1 , Manyi Xu 1 , Lulu Zhang 1 , Zhichao Lei 1 , Cheng Chen 1 , Tianyuan Zhang 1 , Li Chen 1 , Jianbo Sun 1
Affiliation
![]() |
To discover celastrol (CEL) derivatives with enhanced Hsp90–Cdc37 inhibition, C-20-COOH was introduced with various substituted imidazoles, which might affect the Michael addition of CEL by nucleophilic attack. The most potent compound 9, which showed higher antiproliferation, covalent-binding ability, and Hsp90–Cdc37 inhibition than CEL, was selected from 28 new target compounds. Then, the binding sites and the docking mode of 9 to Hsp90 and Cdc37 were studied. Furthermore, the activity of 9 sharply decreased or even disappeared in the Hsp90- and/or Cdc37-overexpressing A549 cells, indicating that the activity was related to its combination with Hsp90 and Cdc37. Moreover, 9 could more effectively induce apoptosis and inhibit tumor growth than CEL in vivo. This study first found that imidazoles linked to C-20 of CEL might affect its Michael addition, which will provide support of CEL or even the other Michael acceptors for the development as antitumor agents.
中文翻译:
发现具有体外和体内抗癌活性的新型 Celastrol-咪唑衍生物
为了发现具有增强的 Hsp90–Cdc37 抑制作用的 celastrol (CEL) 衍生物,C-20-COOH 被引入了各种取代的咪唑,这可能会通过亲核攻击影响 CEL 的迈克尔加成。从 28 种新的目标化合物中选出最有效的化合物9,它显示出比 CEL 更高的抗增殖、共价结合能力和 Hsp90–Cdc37 抑制作用。然后,研究了9与Hsp90和Cdc37的结合位点和对接方式。此外,在过表达 Hsp90 和/或 Cdc37 的 A549 细胞中, 9的活性急剧下降甚至消失,表明该活性与其与 Hsp90 和 Cdc37 的组合有关。此外,9体内比 CEL 能 更 有效 地 诱导 细胞 凋亡 和 抑制 肿瘤 生长. 本研究首次发现与CEL的C-20连接的咪唑类可能会影响其迈克尔加成,这将为CEL甚至其他迈克尔受体作为抗肿瘤药物的发展提供支持。
更新日期:2022-03-03
中文翻译:

发现具有体外和体内抗癌活性的新型 Celastrol-咪唑衍生物
为了发现具有增强的 Hsp90–Cdc37 抑制作用的 celastrol (CEL) 衍生物,C-20-COOH 被引入了各种取代的咪唑,这可能会通过亲核攻击影响 CEL 的迈克尔加成。从 28 种新的目标化合物中选出最有效的化合物9,它显示出比 CEL 更高的抗增殖、共价结合能力和 Hsp90–Cdc37 抑制作用。然后,研究了9与Hsp90和Cdc37的结合位点和对接方式。此外,在过表达 Hsp90 和/或 Cdc37 的 A549 细胞中, 9的活性急剧下降甚至消失,表明该活性与其与 Hsp90 和 Cdc37 的组合有关。此外,9体内比 CEL 能 更 有效 地 诱导 细胞 凋亡 和 抑制 肿瘤 生长. 本研究首次发现与CEL的C-20连接的咪唑类可能会影响其迈克尔加成,这将为CEL甚至其他迈克尔受体作为抗肿瘤药物的发展提供支持。